TNF-α signaling is not required for in vivo transcriptional reactivation of latent murine cytomegalovirus

Transplantation

Volumn 88, Issue 5, 2009, Pages 640-645

  Zhang, Zheng ^a   Li, Zhigao ^a   Yan, Shixian ^a   Wang, Xueqiong ^a   Abecassis, Michael ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cytomegalovirus; TNF; Transplantation; Viral Reactivation

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; GENE EXPRESSION; IN VIVO STUDY; ISOGRAFT; KIDNEY TRANSPLANTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; VIRUS REACTIVATION; ANIMAL; B LYMPHOCYTE; BAGG ALBINO MOUSE; BETAHERPESVIRINAE; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GRAFT REJECTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; VIROLOGY;

ANIMALS; B-LYMPHOCYTES; CYTOMEGALOVIRUS INFECTIONS; GENE EXPRESSION REGULATION; GRAFT REJECTION; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL; MUROMEGALOVIRUS; NF-KAPPA B; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349570584     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b242a7     Document Type: Article

References (40)

1. Razonable RR, Paya CV. Beta-Herpesviruses in transplantation. Rev Med Microbiol 2002; 13: 163.
2. Reddehase MJ, Simon CO, Seckert CK, et al. Murine model of cytomegalovirus latency and reactivation. Curr Top Microbiol Immunol 2008; 325: 315.
3. 3. Kurz SK, Rapp M, Steffens HP, et al. Focal transcriptional activity of murine cytomegalovirus during latency in the lungs. J Virol 1999; 73: 482. (Pubitemid 28565393)
4. 4. Simon CO, Seckert CK, Dreis D, et al. Role for tumor necrosis factor alpha in murine cytomegalovirus transcriptional reactivation in latently infected lungs. J Virol 2005; 79: 326. (Pubitemid 39648387)
5. 5. Grzimek NK, Dreis D, Schmalz S, et al. Random, asynchronous, and asymmetric transcriptional activity of enhancer-flanking major immediate-early genes ie1/3 and ie2 during murine cytomegalovirus latency in the lungs. J Virol 2001; 75: 2692. (Pubitemid 32185033)
6. Henry SC, Hamilton JD. Detection of murine cytomegalovirus immediate early 1 transcripts in the spleens of latently infected mice. J Infect Dis 1993; 167: 950.
7. Yuhasz SA, Dissette VB, Cook ML, et al. Murine cytomegalovirus is present in both chronic active and latent states in persistently infected mice. Virology 1994; 202: 272.
8. Simon CO, Seckert CJ, Grzimek N, et al. Murine model, of cytomegalovirus latency and reactivation: The silencing/desilencing and immune sensing hypothesis. In: Reddehase M, ed. Cytomegaloviruses: Molecular biology and immunology. Norfolk, Caister Academic Press 2006, p 483.
9. Reeves MB, MacAry PA, Lehner PJ, et al. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc Natl Acad Sci USA 2005; 102: 4140.
10. 10. Liu X-F, Yan S, Abecassis M, et al. Establishment of murine cytomegalovirus latency in vivo is associated with changes in histone modifications and recruitment of transcriptional repressors to the major immediate-early promoter. J Virol 2008; 82:10922. (Pubitemid 352691204)
11. 11. Dorsch-Hasler K, Keil GM, Weber F, et al. A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate early mRNA in murine cytomegalovirus. Proc Natl Acad Sci USA 1985; 82: 8325. (Pubitemid 16101071)
12. Meier JL, Stinski MF. Major immediate-early enhancer and its gene products. In: Reddehase MJ, ed. Cytomegaloviruses molecular biology and immunology. Norfolk, Caister Academic Press 2006, p 151.
13. 13. Barnes PJ, Karin M. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066. (Pubitemid 27163860)
14. Hummel M, Abecassis MI. A model for reactivation of CMV from latency. J Clin Virol 2002; 25: S123.
15. Hummel M, Zhang Z, Yan S, et al. Allogeneic transplantation induces expression of cytomegalovirus immediate-early genes in vivo: A model for reactivation from latency. J Virol 2001; 75: 4814.
16. 16. Kim SJ, Varghese TK, Zhang Z, et al. Renal ischemia/reperfusion injury activates the enhancer domain of the human cytomegalovirus major immediate early promoter. Am J Transplant 2005; 5: 1606. (Pubitemid 40916229)
17. 17. Zhang Z, Kim SJ, Varghese T, et al. TNF receptor independent activation of the cytomegalovirus major immediate early enhancer in response to transplantation. Transplantation 2008; 85: 1039. (Pubitemid 351543169)
18. 18. Bubic I, Wagner M, Krmpotic A, et al. Gain, of virulence caused by loss of a gene in murine cytomegalovirus. J Virol 2004; 78: 7536. (Pubitemid 38915900)
19. Brune W, Hengel H, Koszinowski UH. A mouse model for cytomegalovirus infection. In: Coligan JE, Kruisbeek AM, Margulies DH, et al, eds. Current protocols in immunology. New York, NY, John Wiley and Sons, Inc. 1999, p 19.7.1.
20. Zhang Z, Schlachta C, Duff J, et al. Improved techniques for kidney transplantation in mice. Microsurgery 1995; 16: 103.
21. Hummel M, Kurian SM, Lin S, et al. Intragraft TNF receptor signaling contributes to activation of innate and adaptive immunity in a renal allograft model. Transplantation 2009; 87: 178.
22. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10: 45.
23. Lodoen MB, Lanier LL. Viral modulation of NK cell immunity. Nature reviews. Microbiology 2005; 3: 59.
24. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606.
25. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49: 697.
26. Debets JM, Lcunissen KM., van Hooff HJ, et al. Evidence of involvement of tumor necrosis factor in adverse reactions during treatment of kidney allograft rejection with antithymocyte globulin. Transplantation 1989; 47:487.
27. Grant SC, Lamb WR, Brooks NH, et al. Serum cytokines in human heart transplant recipients. Is there a relationship to rejection? Transplantation 1996; 62: 480.
28. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992; 53: 68.
29. Portela D, Patel R, Larson-Keller JJ, et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995; 171: 1014.
30. 30. Mutimer D, Mirza D, Shaw J, et al. Enhanced (cytomegalovirus) viral replication associated with septic bacterial complications in liver transplant recipients. Transplantation 1997; 63: 1411. (Pubitemid 27237443)
31. Fietze E, Prosch S, Reinke P, et al. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 1994; 58: 675.
32. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184: 1461.
33. 33. Docke WD, Prosch S, Fietze E, et al. Cytomegalovirus reactivation and tumour necrosis factor. Lancet 1994; 343: 268. (Pubitemid 24039630)
34. 34. Heininger A, Jahn G, Engel C, et al. Human cytomegalovirus infections in nonimmunosuppressed critically ill patients [see comments], Crit Care Med 2001; 29: 541. (Pubitemid 32225295)
35. 35. Kutza AS, Muhl E, Hackstein H, et al. High incidence of active cytomegalovirus infection among septic patients [sec comments]. Clin Infect Dis 1998; 26: 1076. (Pubitemid 28215467)
36. Prosch S, Staak K, Stein J, et al. Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNF alpha is mediated via induction of NF-kB. Virology 1995; 208: 197.
37. Stein J, Volk HD, Liebenthal C, et al. Tumour necrosis factor alpha stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells. J. Gen Virol 1993; 74(Pt 11): 2333.
38. 38. Cook CH, Trgovcich J, Zimmerman PD, et al. Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1beta triggers reactivation of latent cytomegalovirus in immunocompetent mice. J Virol 2006; 80: 9151. (Pubitemid 44359987)
39. Bolovan-Fritts CA, Mocarski ES, Wiedeman JA. Peripheral blood CD14+ cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood 1999; 93: 394.
40. Baskar JF, Smith PP, Nilaver G, et al. The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice. J Virol 1996; 70: 3207.